drugset / Trial / NCT00254800

The Effects of Exenatide on Oral Contraceptive Pharmacokinetics in Healthy Females

NCT00254800

Phase 1 Completed 38 enrolled AstraZeneca Eli Lilly and Company · collab
RandomizedCrossoverOpen-labelTreatment

Summary

The purpose of this study is the examine the effect of taking exenatide on the blood levels (pharmacokinetics) of orally-administered contraceptives.

Timeline

Start
2005-11
Primary completion
2006-08
Completion
2006-08

Drugs

EvaluationDrugModalityDoseRoute
Subject Exenatide Peptide 10 ug Subcutaneous
Subject Levonorgestrel Small molecule 150 ug Oral
Subject ethinyl estradiol Small molecule 30 ug Oral